《生命科学》 2018, 30(3): 267-275

CDH13在恶性肿瘤中的研究进展

周　婺，王俊杰*

(三峡大学附属仁和医院妇产科/三峡大学妇科肿瘤研究所，宜昌 443001)
    

摘　要：摘　要：T- 钙黏蛋白(T-Cadherin/H-Cadherin， CDH13) 是非典型的钙黏素家族中的一员。研究发现，CDH13广泛分布于正常细胞表面，而在肺癌、乳腺癌、宫颈癌等多种恶性肿瘤中表达下调，并证实与肿瘤的不良预后有关。在肿瘤中CDH13 的再表达可抑制肿瘤细胞的增殖与侵袭。这些特性表明，CDH13 可能成为恶性肿瘤风险评估和监测预后的新的分子生物学标志。现就近年来CDH13 在恶性肿瘤中的研究进展进行综述。

Research progress of CDH13 in malignant tumors

ZHOU Wu， WANG Jun-Jie*

(Department of Gynecology， Affiliated Ren He Hospital of China Three Gorges University-The Institute of Gynecologic Oncology， China Three Gorges University， Yichang 443001， China)

Abstract: Abstract: CDH13 (T-Cadherin/H-Cadherin， CDH13) is an atypical member of the cadherin family. It was found that CDH13 is widely distributed on the surface of normal cells. It is often down-regulated in cancerous cells. CDH13 down-regulation has been associated with poorer prognosis in various carcinomas， such as lung cancer， breast cancer and cervical cancer. CDH13 reexpression in most cancer cell lines inhibits cell proliferation and invasiveness， and increases susceptibility to apoptosis. These properties suggest that CDH13 may represent a possible target for cancer risk and prognosis. This review summarizes the research progress of CDH13 in tumor therapy.